We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery
News

PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery

PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery
News

PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PamGene Enters Co-Marketing Agreement with Invitrogen in Nuclear Hormone Receptor Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PamGene International BV has announced the signing of a co-marketing agreement with Invitrogen Corporation a provider of essential life science technologies for research, production and diagnostics.

Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen's Nuclear Hormone Receptor proteins and Lanthascreen® assay technology with PamGene's portfolio of microarray-based Nuclear Hormone Receptor screening tools; specifically its PamChip® applications and PamStation® instrumentation.

This creates a complete offering for compound screening in drug discovery in the areas of cancer, diabetes and heart disease. The current market for nuclear receptor targeted drugs is estimated to be 10-15% of the $400 billion global pharmaceutical market.

Advertisement